Swarthmore Group’s iShares Biotechnology ETF IBB Stock Holding History

Swarthmore Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-57,150	Closed	-$6.1M	–	37
2018 Q1	$6.1M	Sell	57,150 -1,650	-3%	-$183K	1.45%	26
2017 Q4	$6.28M	Hold	58,800	–	–	1.34%	24
2017 Q3	$6.54M	Sell	58,800 -1,950	-3%	-$208K	1.49%	24
2017 Q2	$6.28M	Buy	60,750 +51,450	+553%	+$5.07M	1.45%	23
2017 Q1	$909K	Sell	9,300 -210,975	-96%	-$20.2M	0.14%	32
2016 Q4	$19.5M	Buy	220,275 +197,550	+869%	+$18M	2.91%	14
2016 Q3	$2.19M	Hold	22,725	–	–	0.42%	32
2016 Q2	$1.95M	Hold	22,725	–	–	0.33%	35
2016 Q1	$1.98M	Hold	22,725	–	–	0.3%	37
2015 Q4	$2.56M	Hold	22,725	–	–	0.27%	32
2015 Q3	$2.3M	Sell	22,725 -310,575	-93%	-$37.3M	0.24%	32
2015 Q2	$41M	Sell	333,300 -10,425	-3%	-$1.25M	3.81%	8
2015 Q1	$39.3M	Buy	+343,725	New	+$37.9M	3.59%	13

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Swarthmore Group's IBB Position: Q2 2018 in Review

Swarthmore Group sold out of iShares Biotechnology ETF (IBB) in Q2 2018, closing a stake of 57,150 shares — an estimated $6.1M sold.

Swarthmore Group first reported a position in IBB in Q1 2015 and held it in 13 quarters. The position peaked at $41M in Q2 2015. 609 funds tracked by Wall St. Rank hold IBB as of Q2 2018.

Swarthmore Group reported no remaining iShares Biotechnology ETF position as of Q2 2018 after selling out during the quarter.
Swarthmore Group sold 57,150 iShares Biotechnology ETF shares in Q2 2018, an estimated $6.1M.
Swarthmore Group first reported a position in iShares Biotechnology ETF in Q1 2015 and held it in 13 quarters.
Swarthmore Group's iShares Biotechnology ETF position peaked at $41M in Q2 2015.
609 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2018.

Based on Swarthmore Group's 13F filing for Q2 2018, filed 18 Jul 2018.